Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study

Benzi Azzolini, C. Pizzomi, E. Guffanti, M. Ronzitti, L. Tantalo

Research output: Contribution to journalArticle

Abstract

This double-blind, randomized, multicentcr clinical study assessed the efficacy and safety of ibopamine 100 mg t.i.d. as monotherapy vs. placebo in 52 patients with mild chronic heart failure aged over 60 years during a 12-weektreatment period. Ibopamine produced a statistically significant increase in exercise tolerance and reduction in fatigue during effort compared to placebo. A trend towards decreased requirement of concomitant diuretic therapy was noted in the ibopaminc-treated group. Ibopamine was well tolerated throughout the study. This study indicated that ibopamine is an effective and safe agent as monotherapy in the treatment of mild chronic heart failure in elderly patients.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalCardiology
Volume77
DOIs
Publication statusPublished - 1990

Keywords

  • Chronic
  • Elderly
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Ibopamine in the treatment of mild chronic heart failure in elderly patients: A double-blind, placebo-controlled study'. Together they form a unique fingerprint.

  • Cite this